These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 29869354)

  • 1. Accepting hepatitis C virus-infected donor hearts for transplantation: Multistep consent, unrealized opportunity, and the Stanford experience.
    Moayedi Y; Gulamhusein AF; Ross HJ; Teuteberg JJ; Khush KK
    Clin Transplant; 2018 Jul; 32(7):e13308. PubMed ID: 29869354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.
    Kwong AJ; Wall A; Melcher M; Wang U; Ahmed A; Subramanian A; Kwo PY
    Am J Transplant; 2019 May; 19(5):1380-1387. PubMed ID: 30378723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart Transplant Using Hepatitis C-Seropositive and Viremic Organs in Seronegative Recipients.
    Zhu Y; Shudo Y; Lee R; Woo YJ
    Ann Transplant; 2020 Jun; 25():e922723. PubMed ID: 32527989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors.
    Frager SZ; Dhand A; Gass A; Levine A; Spielvogel D; Nog R; Wolf DC; Bodin RI
    Cardiol Rev; 2019; 27(4):179-181. PubMed ID: 31180937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience.
    Kapila N; Menon KVN; Al-Khalloufi K; Vanatta JM; Murgas C; Reino D; Ebaid S; Shaw JJ; Agrawal N; Rhazouani S; Navas V; Sheffield C; Rahman AU; Castillo M; Lindenmeyer CC; Miller C; Quintini C; Zervos XB
    Hepatology; 2020 Jul; 72(1):32-41. PubMed ID: 31659775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of heart transplantation from hepatitis C virus-positive donors.
    Aslam S; Yumul I; Mariski M; Pretorius V; Adler E
    J Heart Lung Transplant; 2019 Dec; 38(12):1259-1267. PubMed ID: 31521479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into the rational use of HCV+ organs worldwide.
    Morales JM; Sawinski D
    Clin Transplant; 2019 Dec; 33(12):e13739. PubMed ID: 31648391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C donor viremic cardiac transplantation: A practical approach.
    Morris KL; Adlam JP; Padanilam M; Patel A; Garcia-Cortes R; Chaudhry SP; Seasor E; Tompkins S; Hoefer C; Zanotti G; Walsh MN; Salerno C; Bochan M; Ravichandran A
    Clin Transplant; 2020 Jan; 34(1):e13764. PubMed ID: 31830339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of heart transplantation using hepatitis c-viremic donors: A systematic review with meta-analysis.
    Villegas-Galaviz J; Anderson E; Guglin M
    J Heart Lung Transplant; 2022 Apr; 41(4):538-549. PubMed ID: 35153130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C-positive donor to negative recipient kidney transplantation: A real-world experience.
    Jandovitz N; Nair V; Grodstein E; Molmenti E; Fahmy A; Abate M; Bhaskaran M; Teperman L
    Transpl Infect Dis; 2021 Jun; 23(3):e13540. PubMed ID: 33259125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C.
    Schlendorf KH; Zalawadiya S; Shah AS; Perri R; Wigger M; Brinkley DM; Danter MR; Menachem JN; Punnoose LR; Balsara K; Sacks SB; Ooi H; Awad JA; Sandhaus E; Schwartz C; O'Dell H; Carver AB; Edmonds CL; Ruzevich-Scholl S; Lindenfeld J
    JAMA Cardiol; 2020 Feb; 5(2):167-174. PubMed ID: 31851352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using HCV-viremic organs for lung transplantation does not confer higher rejection rates compared to HCV-negative organs.
    Afshar K; Schonhoft E; Kozuch J; Kafi A; Yung G; Pollema T; Golts E; Aslam S
    Clin Transplant; 2024 Feb; 38(2):e15260. PubMed ID: 38369851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning.
    Bethea E; Arvind A; Gustafson J; Andersson K; Pratt D; Bhan I; Thiim M; Corey K; Bloom P; Markmann J; Yeh H; Elias N; Kimura S; Dageforde LA; Cuenca A; Kawai T; Safa K; Williams W; Gilligan H; Sise M; Fishman J; Kotton C; Kim A; Rogers CC; Shao S; Cote M; Irwin L; Myoung P; Chung RT
    Am J Transplant; 2020 Jun; 20(6):1619-1628. PubMed ID: 31887236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of using hepatitis c virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate.
    Gernhofer YK; Brambatti M; Greenberg BH; Adler E; Aslam S; Pretorius V
    J Heart Lung Transplant; 2019 Nov; 38(11):1178-1188. PubMed ID: 31492607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era.
    Madan S; Patel SR; Rahgozar K; Saeed O; Murthy S; Vukelic S; Sims DB; Shin JJ; Goldstein DJ; Jorde UP
    J Heart Lung Transplant; 2019 Sep; 38(9):907-917. PubMed ID: 31495408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies.
    Schlendorf KH; Zalawadiya S; Shah AS; Wigger M; Chung CY; Smith S; Danter M; Choi CW; Keebler ME; Brinkley DM; Sacks SB; Ooi H; Perri R; Awad JA; Lewis S; Hayes R; O'Dell H; Darragh C; Carver A; Edmonds C; Ruzevich-Scholl S; Lindenfeld J
    J Heart Lung Transplant; 2018 Jun; 37(6):763-769. PubMed ID: 29530322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding access to transplantation with hepatitis C-positive donors: A new perspective on an old issue.
    Kling CE; Limaye AP; Landis CS; Sibulesky L
    Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 28130837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.
    Bethea ED; Gaj K; Gustafson JL; Axtell A; Lebeis T; Schoenike M; Turvey K; Coglianese E; Thomas S; Newton-Cheh C; Ibrahim N; Carlson W; Ho JE; Shah R; Nayor M; Gift T; Shao S; Dugal A; Markmann J; Elias N; Yeh H; Andersson K; Pratt D; Bhan I; Safa K; Fishman J; Kotton C; Myoung P; Villavicencio MA; D'Alessandro D; Chung RT; Lewis GD
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):771-780. PubMed ID: 31353243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.
    La Hoz RM; Sandıkçı B; Ariyamuthu VK; Tanriover B
    Am J Transplant; 2019 Nov; 19(11):3058-3070. PubMed ID: 31207073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report.
    Said A; Weiss M; Varhelyi A; Farago R; Ballweg C; Rice J; Agarwal P; Fernandez L; Foley D
    Transpl Infect Dis; 2021 Apr; 23(2):e13466. PubMed ID: 32931616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.